Shares of CRISPR Therapeutics (NASDAQ: CRSP) slid 18.4% in October, according to data from S&P Global Market Intelligence. The biotech stock lost ground after the company published weaker-than-expected trial results for one of its key clinical therapies. CRISPR published phase 1 trial results for CTX110 on on Oct. 12.
Why is CRSP stock dropping?
Is CRSP a good buy?
Should I hold CRISPR stock?
Is CRSP being shorted?
Is CRSP a buy Zacks?
...
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.97% |
| 2 | Buy | 18.45% |
| 3 | Hold | 10.03% |
| 4 | Sell | 5.70% |
Who owns CRSP stock?
| Stockholder | Stake | Shares owned |
|---|---|---|
| Ecor1 Capital LLC | 1.40% | 1,077,483 |
| Bellevue Asset Management AG | 1.26% | 974,684 |
| BlackRock Fund Advisors | 1.21% | 930,081 |
| Armistice Capital LLC | 1.16% | 892,000 |
Is CRSP overvalued?
What is target price for CRSP?
The 21 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 143.00, with a high estimate of 220.00 and a low estimate of 52.00. The median estimate represents a +202.13% increase from the last price of 47.33.
How much does it cost to do Crispr?
| CRISPR/CAS | INTERNAL RATES |
|---|---|
| Targeting/Transgenic vector construction | $700-6000 |
| Electroporation, drug selection | $1,100 |
| Electroporation, alternate ES strain (e.g. C57Bl/6) | $1,250 |
| Expansion of ES colonies, freezing (per clone) | $17 |
Is DraftKings shorted?
Is Cowen stock a buy?
The gene-editing pioneer announced the pricing of a public stock offering
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) are falling today, down by 9.7% as of 1:53 p.m. EST, after the company announced the pricing of a public stock offering. The gene-editing pioneer said it will offer up to 4.89 million shares at $64.50 apiece, which would generate gross proceeds of up to $315 million.
So what
CRISPR Therapeutics is exploring many applications for its gene-editing technology. For instance, CTX001 attempts to engineer cells in bone marrow such that the resulting red blood cells generated can function properly and relieve individuals suffering from sickle cell disease or beta thalassemia.
Now what
Even after taking today's tumble into account, shares of CRISPR Therapeutics are up 112% since the beginning of the year. Given a pipeline that is (or soon will be) buzzing with activity, it makes sense for the pharma stock to bolster its cash position.
The Positive Post-Pandemic Narrative of CRSP Stock
With coronavirus cases appearing to have subsided to a much more reasonable level, it’s possible that the fundamentals could clear the way for CRSP stock to have a strong outing in 2021 and beyond.
Technical Worries Abound for CRISPR
Although some of the headline talking points for CRSP stock appear enticing, drilling deeper into the details, you can’t help but feel uneasy about the biotech firm. Mainly, countering fundamentals pose headwinds for CRISPR Therapeutics.
Not for the Risk Averse
I want to be clear that I’m not suggesting that $66 is my price target for CRSP stock. I don’t know where shares will end up. But this isn’t the first time shares have printed a bearish technical pattern and made good on it.
Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics
Vertex Pharmaceuticals (NASDAQ: VRTX) has worked closely with CRISPR Therapeutics (NASDAQ: CRSP) for quite a while to develop a CRISPR gene-editing therapy targeting rare blood diseases. Recently, Vertex expanded a partnership focused on CRISPR gene editing, but it's not with CRISPR Therapeutics. In this Motley Fool Live video recorded on Aug.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.07, marking a +0.56% move from the previous day.
Could CRISPR Therapeutics Stock Help You Retire a Millionaire?
The pandemic has brought a new awareness to genetic medicine and scientific research as a whole. One of the pioneers of the technology is CRISPR Therapeutics (NASDAQ: CRSP). It's making its own news and positioned to be one of the leading companies in this new era of gene-based medicine.
12 Best ARK Stocks To Invest In
In this article, we discuss the 12 best ARK stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best ARK Stocks to Invest In. As technology and growth stocks surged during the pandemic, ARK Investment Management and Cathie Wood became two of retail investors’ favorites over the previous […]
Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights
Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.
Earnings Growth & Price Strength Make CRISPR Therapeutics AG (CRSP) a Stock to Watch
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
How Are Genomics ETFs Responding to Q2 Earnings?
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.
The Case for CRSP Stock
CRISPR Therapeutics isn’t your standard biotech that has one or two products on which its ultimate success rests. It’s one of the companies pushing a broader technology known as CRISPR, or colloquially as “gene editing.”
A Coronavirus Victim?
Even before last week’s sell-off, CRSP stock had struggled. After roaring back from March lows with the rest of the market, the stock stalled out in early July.
Buy the Dip
Whatever the cause, the recent weakness in CRSP stock simply looks like an attractive buying opportunity.
Meet Matt McCall
With his next-generation approach to investing, Matt McCall finds better stocks for you to invest in — not the same old companies over-hyped on Wall Street.